Boosting levels of the neurotransmitter norepinephrine with atomoxetine, a repurposed ADHD medication, may be able to stall neurodegeneration in people with early signs of Alzheimer’s disease, a study conducted at Emory Brain Health Center suggests.
The results were published on December 17 in the journal Brain.
This is one of the first published clinical studies to show a significant effect on the protein Tau, which forms neurofibrillary tangles in the brain in Alzheimer’s. In 39 people with mild cognitive impairment (MCI), six months of treatment with atomoxetine…